Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience

Background/aim: In Turkey, lenalidomide plus dexamethasone (RD) has been used to treat relapsed/refractory multiple myeloma (RRMM) since 2010. This retrospective, single-center study evaluated the efficacy and tolerability of RD in patients with RRMM between October 2010 and June 2016. Materials and methods: Patients' records were reviewed, and overall (OS) and progression-free survival (PFS) were assessed. Results: One hundred and twenty patients (71 males; 59.2%) were included in the study. The median number of prior lines of treatment was one (1-4); 72 patients (60.0%) received RD as second-line therapy and 51 patients (42.5%) had previously undergone autologous stem cell transplantation (ASCT). The overall response rate was 72.5%, with 19% of these patients achieving a complete response. The median length of follow-up and duration of response to RD was 14 months and 19 months, respectively. Median OS and PFS were 32 and 21 months, respectively. Prior ASCT, an overall response, and treatment with RD for >12 cycles were identified as independent prognostic factors for OS and PFS. Adverse events (AEs) occurred in 69 (57.5%) and 14 patients (11.7%) discontinued treatment due to AEs. Conclusions: We found RD to be safe, well tolerated, and effective in RRMM in everyday clinical practice in Turkey.
Turkish Journal of Medical Sciences-Cover
  • ISSN: 1300-0144
  • Yayın Aralığı: 6
  • Yayıncı: TÜBİTAK
Sayıdaki Diğer Makaleler

Peripheral arterial disease increases the risk of multidrug-resistant bacteria and amputation in diabetic foot infections

Murat DİZBAY, Kenan HIZEL, Pınar AYSERT YILDIZ, Tuğba ÖZDİL, Özlem GÜZEL TUNÇCAN

SİBEL OYUCU ORHAN, AHMET TEKTEMUR, NEVZAT GÖZEL, İBRAHİM HANİFİ ÖZERCAN, Servet YOLBAŞ, AHMET YILDIRIM, EBRU ÖNALAN, Süleyman Serdar KOCA

Seyed Ahmad HOSEİNİAN, Davood JAFARİ, Mehdi MAHMOODİ, Kamran ALİMOGHADDAM, Mohammadreza OSTADALİ, Azita Talebzadeh BONAKDAR, Arron Munggela FOMA, Mir Saeed YEKANİNEJAD, Ali Akbar AMİRZARGAR

Tayyaba Gul MALIK, Syed Shoaib AHMED, Roquyya GUL, Muhammad KHALIL, Abrar Ahmed MALIK, Masoom KHAN

The validity and reliability of the Turkish version of the Leicester Cough Questionnaire in COPD patients

Arzu YORGANCIOĞLU, Tuğba GÖKTALAY, Ayşın ŞAKAR COŞKUN, Yavuz HAVLUCU, Seçil SARI, Fikret KURHAN, Pınar ÇELİK

Gökhan KESER, Kenan AKSU, Rafi Haner DİRESKENELİ

Leman Tekin ORGUN, Ebru ARHAN, Kürşad AYDIN, Tunzale RZAYEVA, Tuğba HIRFANOĞLU, AYŞE SERDAROĞLU

Detection of the differences in the apparent diffusion coefficient values in different histopathological types of malignant breast lesions and comparison of cellular region/ stroma ratio and histopathological results

Işıl BAŞARA AKIN, Merih Güray DURAK, Ali İbrahim SEVİNÇ, Pınar BALCI, Ayça ERŞEN DANYELİ, Nevin KÖREMEZLİ KESKİN, Esra YAVUZ GÜRKAN

Betül Siyah BİLGİN, Özgün UYGUR, Demet TEREK, Özge Altun KÖROĞLU, Mehmet YALAZ, Mete AKISÜ, Muhsin Özgür ÇOĞULU, Nilgün KÜLTÜRSAY

Relationship of serum HLA-B alleles and TNF-α with rheumatic heart disease

Bülent BOYACI, Serkan ÜNLÜ, Abdurrahman TUFAN, Azmi EYİOL, Çağrı YAYLA, Mustafa CEMRİ, Rıdvan YALÇIN